ZHAOKE OPHTHALMOLOGY LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.5 HKD | -0.66% |
|
+1.35% | -62.03% |
| Apr. 29 | Zhaoke Ophthalmology Shrinks Loss in 2023 | MT |
| Apr. 08 | Zhaoke Ophthalmology Limited Announces the Resignation of Chen Yu Has as Non-Executive Director | CI |
ETFs positioned on Zhaoke Ophthalmology Limited
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.01% | 4 M€ | -27.92% |
Zhaoke Ophthalmology Ltd is a China-based investment holding company principally engaged in the development, manufacturing and marketing of ophthalmic drugs. The Companyâs products include innovative drugs and generic drugs. The Company âs products are mainly applied in five ophthalmic indications, including dry eye disease (DED), wet age-related macular degeneration (wAMD), diabetic macular edema (DME), myopia and glaucoma.
Sector
Pharmaceuticals
Calendar
2024-08-20
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.389
CNY
Average target price
7.1
CNY
Spread / Average Target
+411.15%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -62.03% | 105M | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- 6622 Stock
- Funds and ETFs Zhaoke Ophthalmology Limited
